Summarizing Clinical Advances in the Management of MET Exon 14 Skipping Mutated–NSCLC

Catherine Shu, MD, Price Family Associate Professor of Medicine and the clinical director of the Thoracic Medical Oncology Service at the Columbia University Herbert Irving Comprehensive Cancer Center

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

December 5th 2025

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

ByStephen Liu, MD

October 1st 2025

Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.

Balazs Halmos, MD, MS, professor, Department of Oncology (Medical Oncology), Department of Medicine (Oncology and Hematology), director, Thoracic Oncology, associate director, Clinical Science, Montefiore Einstein Comprehensive Cancer Center

Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS

ByBalazs Halmos, MD, MS

September 9th 2025

Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

Oncology Fellows Presents a New Drug Cheat Sheet for Fellows

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant